SUNY Upstate

Dr. Stephen L. Graziano

Claim this profile

State University of New York Upstate Medical University

Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
45 drugs studied

Area of expertise

1

Lung Cancer

Global Leader

Stephen L. Graziano has run 12 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II
2

Non-Small Cell Lung Cancer

Stephen L. Graziano has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.

State University Of New York Upstate Medical University

Image of trial facility.

Upstate Cancer Center At Oswego

Clinical Trials Stephen L. Graziano is currently running

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Image of trial facility.

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3

More about Stephen L. Graziano

Clinical Trial Related

5 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Stephen L. Graziano has experience with

  • Carboplatin
  • Pembrolizumab
  • Paclitaxel
  • Pemetrexed
  • Durvalumab
  • Biospecimen Collection

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Stephen L. Graziano specialize in?

Is Stephen L. Graziano currently recruiting for clinical trials?

Are there any treatments that Stephen L. Graziano has studied deeply?

What is the best way to schedule an appointment with Stephen L. Graziano?

What is the office address of Stephen L. Graziano?

Is there any support for travel costs?